Antares Pharma and 4 Stocks in the Trading Spotlight Post Earnings

Antares Pharma (NASDAQ:ATRS) had a loss and missed Wall Street’s expectations, AND came up short on beating the revenue expectation. Adjusted Earnings Per Share decreased to $-0.04 in the quarter versus EPS of $-0.03 in the year-earlier quarter. Revenue Rose 28.32% to $5.8 million from the year-earlier quarter.

Antares Pharma reported adjusted EPS loss of $0.04 per share. By that measure, the company missed the mean analyst estimate of $-0.03. It missed the average revenue estimate of $5.82 million.

ATRS 20130811

SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) delivered a profit and missed Wall Street’s expectations, AND came up short on beating the revenue expectation. Adjusted Earnings Per Share decreased 46.67% to $0.08 in the quarter versus EPS of $0.15 in the year-earlier quarter. Revenue Decreased 27.28% to $29.3 million from the year-earlier quarter.

SciClone Pharmaceuticals, Inc. reported adjusted EPS income of $0.08 per share. By that measure, the company missed the mean analyst estimate of $0.11. It missed the average revenue estimate of $33.3 million.

SCLN 20130811

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) had a loss and beat Wall Street’s expectations, AND beat the revenue expectation. Adjusted Earnings Per Share increased to $-0.37 in the quarter versus EPS of $-0.31 in the year-earlier quarter. Revenue Rose 4275% to $14 million from the year-earlier quarter.

Ariad Pharmaceuticals Inc. reported adjusted EPS loss of $0.37 per share. By that measure, the company beat the mean analyst estimate of $-0.4. It beat the average revenue estimate of $11.11 million.

ARIA 20130811

Steris Corp. (NYSE:STE) delivered a profit and missed Wall Street’s expectations, AND came up short on beating the revenue expectation. Adjusted Earnings Per Share decreased 16.98% to $0.44 in the quarter versus EPS of $0.53 in the year-earlier quarter. Revenue Rose 9.12% to $367.7 million from the year-earlier quarter.

Steris Corp. reported adjusted EPS income of $0.44 per share. By that measure, the company missed the mean analyst estimate of $0.56. It missed the average revenue estimate of $372.69 million.

STE 20130811

Valeant Pharmaceuticals International (NYSE:VRX) delivered a profit and beat Wall Street’s expectations, AND beat the revenue expectation. Adjusted Earnings Per Share increased 131.03% to $1.34 in the quarter versus EPS of $0.58 in the year-earlier quarter. Revenue Rose 33.62% to $1.1 billion from the year-earlier quarter.

Valeant Pharmaceuticals International reported adjusted EPS income of $1.34 per share. By that measure, the company beat the mean analyst estimate of $1.28. It beat the average revenue estimate of $297.08 million.

VRX 20130811

Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.